GeneDx Holdings Corp. (WGS)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

7 annual periodsNewest to oldest
2025202420232022202120202019
Revenue$427.5M$305.4M$202.6M$234.7M$212.2M$179.3M$196.2M
Gross profit$298.2M$194.4M$90.0M−$26.8M−$16.6M$4.0M$82.8M
Research & development$72.0M$45.7M$58.3M$86.2M$105.2M$72.7M$34.9M
Operating income−$13.1M−$23.2M−$180.6M−$667.7M−$446.1M−$242.0M−$30.4M
EBITDAderived−$3.5M−$15.3M−$160.9M−$617.7M−$424.3M−$230.3M−$24.0M
Net income−$21.0M−$52.3M−$175.8M−$549.0M−$245.4M−$241.3M−$29.7M
Basic EPSper diluted share-$0.73-$1.94-$7.23-$53.63-$2.27-$47,036.00-$264,056.00
Diluted EPSper diluted share-$0.73-$1.94-$7.23-$53.63-$2.27-$47,036.00-$264,056.00

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys42$115.21M disclosed value
Sells (SEC code S)269$233.10M disclosed value
250 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 16, 2026Form 4Feeley KevinCHIEF FINANCIAL OFFICERSellClass A Common Stock863$61.50$53.1K40.0K
Jun 16, 2026Form 4Feeley KevinCHIEF FINANCIAL OFFICERSellClass A Common Stock2.1K$60.83$128.1K40.8K
Jun 16, 2026Form 4Feeley KevinCHIEF FINANCIAL OFFICERSellClass A Common Stock760$59.75$45.4K42.9K
Jun 16, 2026Form 4Stueland KatherineCHIEF EXECUTIVE OFFICERSellClass A Common Stock2.4K$61.50$149.4K104.4K
Jun 16, 2026Form 4Stueland KatherineCHIEF EXECUTIVE OFFICERSellClass A Common Stock5.9K$60.83$360.8K106.8K